TACE联合阿帕替尼治疗中晚期肝细胞癌

发布时间：2018-03-21 17:08

本文选题：癌　切入点：肝细胞　出处：《中国介入影像与治疗学》2017年04期 　论文类型：期刊论文

【摘要】：目的比较TACE联合阿帕替尼与单纯TACE治疗中晚期肝细胞癌的临床疗效和安全性。方法将44例肝细胞癌患者随机平均分为A、B组,对A组行单纯TACE治疗,B组行TACE联合阿帕替尼治疗。比较两组治疗后3个月时甲胎蛋白(AFP)指标变化,及3、6、9、12个月时客观缓解率(ORR)。同时比较两组患者疾病无进展生存期(PFS)和不良反应的发生情况。结果治疗后3个月,A、B组AFP水平均显著下降,较治疗前差异均有统计学意义(Z=-2.289、-2.953,P均0.05),治疗后两组间比较差异无统计学意义(Z=-0.126,P=0.90)。3、6个月时两组ORR差异无统计学意义(P均0.05),9、12个月时差异有统计学意义(P均0.05)。两组PFS差异有统计学意义(X~2=6.576,P=0.01)。B组阿帕替尼相关并发症(包括高血压、手足综合征、蛋白尿)发生率高于A组,差异均有统计学意义(P均0.05)。不良反应经对症处理后均缓解。结论对于中晚期肝细胞癌患者,TACE联合阿帕替尼的中远期疗效优于单纯TACE治疗,且具有一定的安全性。
[Abstract]:Objective to compare the clinical efficacy and safety of TACE combined with apatinib and TACE alone in the treatment of advanced hepatocellular carcinoma (HCC). Group A was treated with TACE alone and group B was treated with TACE combined with apatinib. The objective remission rate was compared between the two groups at the same time. The incidence of AFP and adverse reactions were compared between the two groups. Results after 3 months of treatment, the levels of AFP in group A were significantly lower than those in group A (P < 0.05). After treatment, there was no significant difference in ORR between the two groups. There was no significant difference in ORR between the two groups after treatment. There was no significant difference in ORR between the two groups at 6 months after treatment (P < 0.05), and there was a significant difference in PFS between the two groups at 12 months (P < 0.05). Statistical significance: Apatini-associated complications (including hypertension) in group B: 6.576%. The incidence of hand and foot syndrome (proteinuria) was higher than that of group A. The difference was statistically significant (P < 0.05). The adverse reactions were alleviated after symptomatic treatment. Conclusion the mid- and long-term efficacy of TACE combined with apatinib in patients with advanced hepatocellular carcinoma is better than that of TACE alone, and it is safe to some extent.
【作者单位】：南方医科大学第三临床医学院;南方医科大学附属海军总医院介入医学科;
【基金】：中国人民解放军海军总医院人才引进专项基金(RCYJZX-009)
【分类号】：R735.7

【相似文献】